OUR APPROACH
Discover. Develop. Deliver.
We are taking a holistic approach towards developing effective treatments for UBA5 with a focus on gene therapy as our first solution. We will be operating like a lean startup, meaning we will be fast, efficient and cross-functional. We know that our work will ultimately benefit countless kids suffering from rare diseases around the world.
OUR RESEARCH PROCESS
OUR SCIENCE PARTNERS
New: Translational Institute for Molecular Therapeutics
Learn about the Gray-Edwards Lab
Learn about the Sena-Esteves Lab
Meet Dr. Guangping Gao, A Pioneer in AAV Gene Therapy
UMASS CHAN
LEARN MORE
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
GENE REPLACEMENT THERAPY
The UMass Chan Medical School research team will develop an adeno-associated virus gene therapy to correct the UBA5 deficiency. This preclinical development will lead to an investigational new drug application to the FDA.
LEARN MORE
BAYLOR
COLLEGE OF MEDICINE
DRUG REPURPOSING
The Bellen Lab at Baylor College of Medicine aims to model patient UBA5 mutations using the fruit fly model to screen drugs that may correct disease causing defects in UBA5 patients.
LEARN MORE
ST. JUDE
CHILDREN'S RESEARCH HOSPITAL
TREATMENT EXPLORATION
The Mefford lab at St. Jude Children’s Research Hospital is actively investigating approaches to increase amounts of the UBA5 protein in children affected by UBA5-related disorder.
LEARN MORE
OHSU
OREGON HEALTH AND SCIENCE UNIVERSITY
BASIC SCIENCE
The Pruneda Lab at Oregon Health & Science University will use a biochemical and protein chemistry approach to investigate how patient UBA5 mutations affect the normal function of the protein UBA5.
